AbbVie's Strategic Acquisition of Apogee Therapeutics to Bolster Immunology Portfolio
Money

AbbVie's Strategic Acquisition of Apogee Therapeutics to Bolster Immunology Portfolio

authorBy Natalie Pace
DateJun 27, 2026
Read Time2 min

AbbVie Inc. (NYSE: ABBV), a prominent research-based pharmaceutical company, has confirmed its intention to acquire Apogee Therapeutics. This strategic move, announced on June 22, will see AbbVie incorporate Apogee's diverse range of clinical-stage candidates, currently in development for immunological and inflammatory conditions such as asthma and atopic dermatitis. The leadership of AbbVie views this acquisition as a crucial step to complement its current immunology offerings and expand its involvement in the respiratory health sector.

The terms of the agreement stipulate that AbbVie will purchase all outstanding shares of Apogee at $135.11 per share in cash, reflecting a total equity valuation for Apogee of approximately $10.9 billion. This significant transaction has received unanimous approval from the boards of directors of both companies and is projected to finalize in the third fiscal quarter of 2026. The completion remains subject to standard closing conditions, including endorsement from Apogee shareholders and the receipt of necessary regulatory approvals.

AbbVie is recognized for its dedication to developing and commercializing treatments for various chronic diseases across multiple therapeutic areas, including oncology, gastroenterology, rheumatology, dermatology, and virology. This acquisition further underscores AbbVie's commitment to innovation and growth in critical health domains. Such strategic integrations demonstrate how established pharmaceutical entities seek to broaden their impact and address unmet medical needs, fostering advancements in patient care and global health initiatives.

More Articles
Money
Eli Lilly and BioArctic Forge Alliance for Neurodegenerative Treatment
Eli Lilly and Company and BioArctic AB have entered into a research and collaboration agreement to develop a novel treatment for neurodegeneration. This partnership combines BioArctic's BrainTransporter technology with an undisclosed Lilly drug candidate. BioArctic stands to receive a $30 million upfront payment and potential milestone payments up to $770 million, plus royalties on future global sales. Eli Lilly will manage global development and commercialization. The collaboration aims to address critical needs in neuroscience with innovative pharmaceutical solutions.
By Chika UwazieJun 27, 2026
Money
Starbucks' Ambitious Expansion: A Strategy to Redefine the Coffee Experience
Starbucks CEO Brian Niccol is steering the company towards an ambitious expansion plan, aiming to add 10,000 new U.S. locations. This strategy involves smaller store formats and a renewed focus on community and personalized customer experiences, moving beyond its pandemic-era takeout model. Niccol emphasizes creating a 'third place' for connection and customization, believing this approach will drive long-term growth and differentiate Starbucks from competitors like Dutch Bros and 7 Brew.
By Bola SokunbiJun 27, 2026
Money
Scotiabank Adjusts Price Target for América Móvil Amid Telecom Market Shifts
Scotiabank has lowered its price target for América Móvil (AMX) to $20.80 from $21.80, while maintaining a Sector Perform rating. This adjustment reflects a reevaluation of LatAm Telecom stocks, influenced by a reduced global risk premium for equities compared to bonds. América Móvil, a major telecommunications provider, recently reported robust Q1 2026 results, including a significant increase in postpaid wireless subscribers and strong mobile service revenue growth, underscoring its operational strength despite the updated valuation.
By Mr. Money MustacheJun 27, 2026
Money
Bank of America Upgrades American Airlines' Price Target Amidst Strong Demand
Bank of America (BofA) has increased its price target for American Airlines (AAL) to $16 from $14, maintaining a Neutral rating. This adjustment reflects an improved outlook for airlines due to robust travel demand and positive market performance as the second fiscal quarter earnings season approaches. American Airlines reported record first-quarter revenues of $13.9 billion and significantly reduced its total debt to $34.7 billion, the lowest level since mid-2015.
By Scott PapeJun 27, 2026
Money
Rockwell Automation (ROK) Automates Cranswick's Packaging System
Rockwell Automation (ROK) has partnered with Cranswick to implement a robotic pick-and-place system for automating their Christmas 'pigs-in-blankets' packaging. This advancement transitions manual tasks to automated processes, freeing employees for more skilled roles. DA Davidson initiated a 'Neutral' rating for Rockwell, citing its strong market position in automation and AI, despite current valuation concerns. The company also recently authorized an additional $1 billion in common stock repurchases.
By Chika UwazieJun 27, 2026